Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (123)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Williamson, M. P.
Right arrow Articles by Knowles, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williamson, M. P.
Right arrow Articles by Knowles, M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 Oxford University Press

OTHER

p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer

Magall P. Williamson+, Patricia A. Elder, Margaret E. Shaw, Jayne Devlin and Margaret A. Knowles*

Molecular Genetics Laboratory, Marie Curie Research Institute The Chart, Oxted, Surrey RH8 OTL, UK

*To whom correspondence be addressed

Received March 29, 1995; Revised June 23, 1995; Accepted June 23, 1995

The p16 gene has been identified as a candidate tumour suppressor gene at 9p21, a region commonly deleted in bladder cancer. We screened 140 bladder tumours and 16 cell lines for deletions and sequence variants of p16. Eight cell lines showed homozygous deletion of p16 and two had small sequence variations. All 13 tumours with small defined deletions of 9p21, 18/31 (58%) of tumours with monosomy 9 and 9/91 (10%) of tumours with no chromosome 9 loss of heterozygosity had homozygous deletion of p16. No tumour-specific sequence variants were identified. Deletion mapping revealed a nested set of deletions focused on p16. Six deletions involved p16 but not the related and adjacent gene p15 and one tumour had an intragenic deletion of p16. All other deletions involved both p16 and p15. We conclude that p16 represents the major target for deletion at 9p21 in bladder cancer.

+Present address: Department of Paediatrics, The Rayne Institute, UCL Medical School, University Street, London WCIE 6JJ, UK


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
Y.-L. Zheng, C. A. Loffredo, P. G. Shields, and S. M. Selim
Chromosome 9 arm-specific telomere length and breast cancer risk
Carcinogenesis, August 1, 2009; 30(8): 1380 - 1386.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Veerakumarasivam, H. E. Scott, S.-F. Chin, A. Warren, M. J. Wallard, D. Grimmer, K. Ichimura, C. Caldas, V. P. Collins, D. E. Neal, et al.
High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53
Clin. Cancer Res., May 1, 2008; 14(9): 2527 - 2534.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. J. MacLaine, M. D. Wood, J. C. Holder, R. W. Rees, and J. Southgate
Sensitivity of Normal, Paramalignant, and Malignant Human Urothelial Cells to Inhibitors of the Epidermal Growth Factor Receptor Signaling Pathway
Mol. Cancer Res., January 1, 2008; 6(1): 53 - 63.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Mian, M Lodde, E Comploj, L Lusuardi, S Palermo, M Mian, K Maier, and A Pycha
Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer.
J. Clin. Pathol., September 1, 2006; 59(9): 984 - 987.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. A. Knowles
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Carcinogenesis, March 1, 2006; 27(3): 361 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Moussa, J. S. Yordy, H. Abol-Enein, D. Sinha, N. K. Bissada, P. V. Halushka, M. A. Ghoneim, and D. K. Watson
Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer
Cancer Res., December 15, 2005; 65(24): 11581 - 11587.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Cheng, T. D. Jones, R. P. McCarthy, J. N. Eble, M. Wang, G. T. MacLennan, A. Lopez-Beltran, X. J. Yang, M. O. Koch, S. Zhang, et al.
Molecular Genetic Evidence for a Common Clonal Origin of Urinary Bladder Small Cell Carcinoma and Coexisting Urothelial Carcinoma
Am. J. Pathol., May 1, 2005; 166(5): 1533 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
J. S. Aveyard and M. A. Knowles
Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification
J. Mol. Diagn., November 1, 2004; 6(4): 356 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. O. Hoque, C.-C. R. Lee, P. Cairns, M. Schoenberg, and D. Sidransky
Genome-Wide Genetic Characterization of Bladder Cancer: A Comparison of High-Density Single-Nucleotide Polymorphism Arrays and PCR-based Microsatellite Analysis
Cancer Res., May 1, 2003; 63(9): 2216 - 2222.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Berggren, R. Kumar, S. Sakano, L. Hemminki, T. Wada, G. Steineck, J. Adolfsson, P. Larsson, U. Norming, H. Wijkstrom, et al.
Detecting Homozygous Deletions in the CDKN2A(p16INK4a)/ARF(p14ARF) Gene in Urinary Bladder Cancer Using Real-Time Quantitative PCR
Clin. Cancer Res., January 1, 2003; 9(1): 235 - 242.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. Wang, T. Habuchi, T. Takahashi, K. Mitsumori, T. Kamoto, Y. Kakehi, H. Kakinuma, K. Sato, A. Nakamura, O. Ogawa, et al.
Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer
Carcinogenesis, February 1, 2002; 23(2): 257 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pathol.Home page
M A Knowles
What we could do now: molecular pathology of bladder cancer
Mol. Pathol., August 1, 2001; 54(4): 215 - 221.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. M. Stadler, G. Steinberg, X. Yang, F. Hagos, C. Turner, and O. I. Olopade
Alterations of the 9p21 and 9q33 Chromosomal Bands in Clinical Bladder Cancer Specimens by Fluorescence in Situ Hybridization
Clin. Cancer Res., June 1, 2001; 7(6): 1676 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
J. A. Randerson-Moor, M. Harland, S. Williams, D. Cuthbert-Heavens, E. Sheridan, J. Aveyard, K. Sibley, L. Whitaker, M. Knowles, J. Newton Bishop, et al.
A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Hum. Mol. Genet., January 1, 2001; 10(1): 55 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Primdahl, H. von der Maase, M. Christensen, H. Wolf, and T. F. Ørntoft
Allelic Deletions of Cell Growth Regulators during Progression of Bladder Cancer
Cancer Res., December 1, 2000; 60(23): 6623 - 6629.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. Sarkar, K. P. Jülicher, M. S. Burger, V. Della Valle, C.-J. Larsen, T. R. Yeager, T. B. Grossman, R. W. Nickells, C. Protzel, D. F. Jarrard, et al.
Different Combinations of Genetic/Epigenetic Alterations Inactivate the p53 and pRb Pathways in Invasive Human Bladder Cancers
Cancer Res., July 1, 2000; 60(14): 3862 - 3871.
[Abstract] [Full Text]

Home page
 Genome ResHome page
J.E. V. Watson, H. Gabra, K. J. Taylor, G. J. Rabiasz, H. Morrison, P. Perry, J. F. Smyth, and D. J. Porteous
Identification and Characterization of a Homozygous Deletion Found in Ovarian Ascites by Representational Difference Analysis
Genome Res., March 1, 1999; 9(3): 226 - 233.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.